BusinessCapricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10By Nasdaq OMXMay 4, 2018, 12:00 PM UTC
BusinessCapricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular DystrophyBy Nasdaq OMXApr 30, 2018, 11:01 AM UTC
BusinessCapricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease ModelBy Nasdaq OMXApr 19, 2018, 11:00 AM UTC
BusinessNew Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular DystrophyBy Nasdaq OMXFeb 22, 2018, 6:22 PM UTC
